Chemotherapy for advanced gastric cancer: Review and update of current practices

Sung Chul Park, Hoon Jai Chun

    Research output: Contribution to journalReview articlepeer-review

    48 Citations (Scopus)

    Abstract

    No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1 or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum, taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine, such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing.

    Original languageEnglish
    Pages (from-to)385-393
    Number of pages9
    JournalGut and liver
    Volume7
    Issue number4
    DOIs
    Publication statusPublished - 2013 Jul

    Keywords

    • Drug therapy
    • Stomach neoplasms

    ASJC Scopus subject areas

    • Hepatology
    • Gastroenterology

    Fingerprint

    Dive into the research topics of 'Chemotherapy for advanced gastric cancer: Review and update of current practices'. Together they form a unique fingerprint.

    Cite this